The Study That Changed the Conversation
At ENDO 2025 in San Francisco, Italian researchers led by Dr. Rossella Cannarella presented a study that surprised even the endocrinology community: tirzepatide outperformed testosterone replacement therapy for improving erectile function in men with obesity and hypogonadism.
This was the first head-to-head comparison of a GLP-1/GIP medication against TRT for sexual function outcomes, and the results challenge assumptions about how best to treat ED in obese men.
Study Design and Results
The study randomized 83 men with obesity and functional hypogonadism (low testosterone caused by obesity, not primary testicular failure) to either tirzepatide or transdermal testosterone gel.
Key findings after treatment:
- Erectile function: Tirzepatide produced greater improvement in erectile function scores than TRT
- Weight loss: 8.1% with tirzepatide vs. 3.0% with TRT
- Waist circumference: Greater reduction with tirzepatide
- Testosterone levels: Both treatments increased total and free testosterone — but through fundamentally different mechanisms
- Gonadotropins (LH, FSH): Tirzepatide increased these hormones; TRT suppressed them
Dr. Cannarella summarized it: tirzepatide appears to be “a safer and more sustainable option” than TRT for men whose low testosterone is driven by obesity.
Why Tirzepatide Beat TRT for ED
The result seems counterintuitive — how can a weight loss drug outperform actual testosterone for sexual function? The answer lies in what causes ED in obese men.
Erectile dysfunction in obesity is primarily a vascular problem, not purely a hormonal one. Excess visceral fat damages blood vessel lining, promotes inflammation, impairs nitric oxide production, and creates insulin resistance — all of which compromise blood flow to the penis. TRT addresses the hormonal piece but doesn’t fix the vascular damage. Tirzepatide addresses both by reducing the fat that’s causing the problem.
Additionally, tirzepatide restores the body’s own testosterone production (shown by rising LH/FSH), while TRT shuts down natural production entirely. A body making its own testosterone in response to improved health may function better sexually than one dependent on external supplementation.
This study examined functional hypogonadism (low T caused by obesity). For men with organic hypogonadism (caused by pituitary or testicular problems), TRT remains the appropriate treatment. A proper diagnosis matters — ask your doctor to determine the cause of your low testosterone, not just treat the number.
Ready to Explore GLP-1 Options?
Compare vetted telehealth providers offering compounded semaglutide and tirzepatide for men.
ⓘ We may earn a commission at no cost to you. See all providers →
What This Means for You
If you’re an obese man with both low testosterone and erectile dysfunction, this study suggests a clear treatment pathway: try GLP-1/GIP therapy first. If weight loss and natural testosterone recovery resolve your ED, you’ve avoided the lifelong commitment, fertility risks, and potential side effects of TRT.
Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss) is the specific medication studied, but semaglutide likely offers similar vascular benefits through weight loss and anti-inflammatory effects.
Medical Disclaimer
This content is for educational purposes only and should not be considered medical advice. GLP-1 medications require a prescription and medical supervision. Always consult a licensed healthcare provider before starting any medication. Compounded medications are NOT FDA-approved.